Synoptis Industrial SP .zo.o

Synoptis Industrial Sp. z o.o. is a Polish pharmaceutical company specializing in the import and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Toruń, Poland, at ul. Forteczna 35-37, the company operates as a subsidiary of the Neuca S.A. Capital Group, a leading pharmaceutical wholesaler in Poland listed on the Warsaw Stock Exchange. Neuca S.A. has over 30 years of experience in the pharmaceutical industry, serving the pharmacy, hospital, and medical markets.

Synoptis Industrial plays a pivotal role in Poland's pharmaceutical distribution network by importing a diverse range of pharmaceutical products and medical devices. The company's operations encompass quality control testing, packaging, labeling, serialization, warehousing, transport, and clinical trial logistics. This comprehensive service offering positions Synoptis Industrial as a key player in ensuring the availability and distribution of essential pharmaceutical products across Poland.

Synoptis Industrial's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Poland. The company's logistics capabilities include warehousing, transport, and clinical trial logistics, which are integral to its operations. While specific details about warehouse locations and geographic coverage are not publicly disclosed, Synoptis Industrial's affiliation with Neuca S.A., the largest pharmaceutical wholesaler in Poland, suggests a well-established and extensive distribution infrastructure. This infrastructure likely facilitates the company's ability to serve the pharmacy, hospital, and medical markets effectively.

In Poland's pharmaceutical supply chain, Synoptis Industrial Sp. z o.o. functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from various international suppliers, including India, and manages their distribution within Poland. Synoptis Industrial's comprehensive services, such as quality control testing, packaging, labeling, serialization, warehousing, transport, and clinical trial logistics, underscore its role as a key intermediary between international manufacturers and the Polish market.

Synoptis Industrial's sourcing strategy exhibits a high degree of concentration, with a total import value of $7.3 million USD from India over 156 shipments, primarily from a single supplier, Macleods Pharmaceuticals Limited. This single-source dependency may present risks, such as supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities. However, the consistent volume of imports and the long-standing relationship with Macleods Pharmaceuticals Limited suggest a stable and reliable partnership. The company's focus on a limited number of suppliers may also allow for more favorable terms and streamlined logistics. Nonetheless, diversifying the supplier base could mitigate potential risks associated with over-reliance on a single source.

Synoptis Industrial's supply chain resilience is closely tied to its relationship with Macleods Pharmaceuticals Limited, the sole supplier of its imported pharmaceutical products. The company's import data indicates a consistent flow of shipments, reflecting a stable supply chain. However, the lack of publicly available information regarding backup suppliers and the diversity of formulations imported suggests a potential vulnerability to disruptions. To enhance resilience, Synoptis Industrial could consider establishing relationships with additional suppliers and diversifying its product portfolio. Ensuring that all suppliers comply with international Good Manufacturing Practice (GMP) standards is crucial for maintaining product quality and regulatory compliance.

Synoptis Industrial's concentrated sourcing strategy positions the company to negotiate favorable terms with Macleods Pharmaceuticals Limited, potentially securing competitive pricing and reliable supply. This focus may also streamline logistics and inventory management. However, the over-reliance on a single supplier exposes Synoptis Industrial to risks such as supply chain disruptions and limited bargaining power in the event of price increases or changes in supply conditions. For Indian exporters, the existing relationship between Synoptis Industrial and Macleods Pharmaceuticals Limited may present challenges in entering this market segment. To position themselves as alternative suppliers, Indian exporters would need to demonstrate superior product quality, competitive pricing, and the ability to meet Synoptis Industrial's logistical and regulatory requirements.

In Poland, the Chief Pharmaceutical Inspectorate (GIF) is the primary regulatory authority overseeing the import and distribution of medicinal products. The Pharmaceutical Law of 6 September 2001, as amended, governs the importation of medicinal products into Poland. According to this legislation, any activity involving the importation of a medicinal product into Poland from outside the European Union or European Free Trade Association (EFTA) countries, which includes storage, quality control at batch release, and distribution, constitutes an import requiring GIF authorization. (cms.law)

Importers of medicinal products into Poland must obtain authorization from the Chief Pharmaceutical Inspectorate (GIF). This authorization is mandatory for activities such as storage, quality control at batch release, and distribution of imported medicinal products. (cms.law) Additionally, imported pharmaceutical products must comply with international Good Manufacturing Practice (GMP) standards, such as EU GMP, WHO GMP, or PIC/S certifications, to ensure product quality and safety. Importers are also required to hold a wholesale distribution authorization to legally distribute medicinal products within Poland.

Imported pharmaceutical products must undergo batch testing to ensure compliance with Polish and European Union standards. Stability requirements are enforced to guarantee the efficacy and safety of medicinal products throughout their shelf life. Labeling must be in Polish and include all necessary information as stipulated by Polish regulations, such as product name, active ingredients, dosage form, strength, and instructions for use. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

In July 2024, Poland's Chief Pharmaceutical Inspectorate (GIF) issued a ruling clarifying the definition of "import" under the Pharmaceutical Law. The decision specified that activities involving the importation of a medicinal product into Poland from outside the EU or EFTA, including storage, quality control at batch release, and distribution, require GIF authorization. This ruling underscores the importance of compliance with Polish regulations for all entities involved in the import and distribution of medicinal products. (cms.law)

Synoptis Industrial's product strategy focuses on importing pharmaceutical formulations in the cardiovascular and antiviral therapeutic categories. The company's top five imported products include Rosuvastatin, Emtricitabine, Clopidogrel, and Efavirenz, which are essential in managing cardiovascular diseases and HIV infections. The market demand for these products is driven by the prevalence of cardiovascular conditions and HIV in Poland, necessitating a steady supply of effective treatments. By concentrating on these therapeutic areas, Synoptis Industrial aligns its product offerings with critical healthcare needs in the Polish market.

Synoptis Industrial's sourcing strategy is centered on importing generic pharmaceutical formulations from India, particularly from Macleods Pharmaceuticals Limited. The company's focus on finished pharmaceutical products, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market solutions that meet Polish regulatory standards. India's robust pharmaceutical manufacturing sector, known for its compliance with international GMP standards, makes it a strategic sourcing partner for Synoptis Industrial.

Based on its product mix, Synoptis Industrial serves multiple segments of the Polish pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential medications for cardiovascular and antiviral treatments positions it to meet the needs of both outpatient and inpatient care settings. Additionally, Synoptis Industrial's involvement in clinical trial logistics suggests a role in supporting research and development initiatives within the healthcare sector.

There is a potential opportunity for new Indian suppliers to enter the Polish market by partnering with Synoptis Industrial. To capitalize on this opportunity, Indian exporters should focus on offering high-quality generic formulations that comply with EU GMP standards, competitive pricing, and reliable supply capabilities. Identifying and addressing any gaps in Synoptis Industrial's current sourcing, such as unmet therapeutic needs or product shortages, could further enhance the attractiveness of new suppliers.

Indian exporters aiming to supply Synoptis Industrial and the Polish market must ensure that their products meet international GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, obtaining marketing authorization from the Chief Pharmaceutical Inspectorate (GIF) is essential for the legal distribution of medicinal products in Poland. Compliance with Polish labeling requirements, including the use of the Polish language and adherence to serialization mandates, is also necessary.

To establish a relationship with Synoptis Industrial, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with relevant regulatory standards.